Moderna, Inc. Peer Comparison
Metric | Value | Ranking | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap | $11.8 Billion | 2/17 | VRTX $117.2B |
MRNA $11.8B |
RETA $6.6B |
KRYS $4.4B |
BEAM $2.4B |
NVAX $1.3B |
NTLA $968.6M |
CVAC $823.2M |
DNA $708.1M |
EDIT $98.2M |
ELEV $36.7M |
RAIN $26.1M |
OCEA $5.9M |
AVRO $5.2M |
ENVB $3.0M |
HEPA $2.1M |
CWBR $1.2M |
Gross Margin | 72% | 7/17 | NTLA 100% |
RETA 96% |
CVAC 96% |
KRYS 90% |
DNA 89% |
VRTX 86% |
MRNA 72% |
BEAM 62% |
NVAX 28% |
CWBR 0% |
AVRO 0% |
HEPA 0% |
RAIN 0% |
ELEV 0% |
OCEA 0% |
ENVB 0% |
EDIT -100% |
Profit Margin | 1% | 5/17 | RETA 100% |
CVAC 68% |
VRTX 38% |
KRYS 32% |
MRNA 1% |
CWBR 0% |
AVRO 0% |
HEPA 0% |
RAIN 0% |
ELEV 0% |
OCEA 0% |
ENVB 0% |
DNA -63% |
NVAX -100% |
EDIT -100% |
NTLA -100% |
BEAM -100% |
EBITDA margin | -4% | 4/17 | CVAC 76% |
VRTX 40% |
KRYS 27% |
MRNA -4% |
DNA -62% |
CWBR -100% |
AVRO -100% |
HEPA -100% |
RAIN -100% |
ELEV -100% |
OCEA -100% |
ENVB -100% |
NVAX -159% |
RETA -356% |
BEAM -639% |
NTLA -1490% |
EDIT -101870% |
Quarterly Revenue | $1.9 Billion | 2/17 | VRTX $2.8B |
MRNA $1.9B |
CVAC $542.7M |
DNA $89.0M |
NVAX $84.5M |
KRYS $83.8M |
RETA $22.7M |
BEAM $14.3M |
NTLA $9.1M |
EDIT $61,000 |
CWBR $0 |
AVRO $0 |
HEPA $0 |
RAIN $0 |
ELEV $0 |
OCEA $0 |
ENVB $0 |
Quarterly Earnings | $13.0 Million | 5/17 | VRTX $1.0B |
CVAC $371.5M |
RETA $193.0M |
KRYS $27.2M |
MRNA $13.0M |
ENVB -$2.1M |
RAIN -$3.0M |
CWBR -$4.3M |
HEPA -$4.9M |
OCEA -$5.5M |
AVRO -$6.8M |
ELEV -$12.9M |
DNA -$56.4M |
EDIT -$62.1M |
BEAM -$96.7M |
NVAX -$121.3M |
NTLA -$135.7M |
Quarterly Free Cash Flow | -$1.7 Million | 16/17 | VRTX $1.5B |
CVAC $385.5M |
KRYS $57.8M |
OCEA -$885,000 |
ENVB -$927,073 |
CWBR -$1.8M |
HEPA -$2.5M |
AVRO -$7.6M |
ELEV -$16.6M |
EDIT -$55.5M |
RETA -$70.2M |
NTLA -$86.1M |
BEAM -$89.7M |
DNA -$118.6M |
NVAX -$145.6M |
MRNA -$1.7B |
RAIN -$0 |
Trailing 4 Quarters Revenue | $5.1 Billion | 2/17 | VRTX $10.6B |
MRNA $5.1B |
NVAX $885.2M |
CVAC $596.5M |
BEAM $349.6M |
KRYS $241.5M |
DNA $218.0M |
EDIT $61.8M |
NTLA $43.1M |
RETA $24.4M |
CWBR $0 |
AVRO $0 |
HEPA $0 |
RAIN $0 |
ELEV $0 |
OCEA $0 |
ENVB $0 |
Trailing 4 Quarters Earnings | -$2.2 Billion | 17/17 | VRTX $2.8B |
MRNA $1.9B |
CVAC $542.7M |
DNA $89.0M |
NVAX $84.5M |
KRYS $83.8M |
RETA $22.7M |
BEAM $14.3M |
NTLA $9.1M |
EDIT $61,000 |
CWBR -$0 |
AVRO -$0 |
HEPA -$0 |
RAIN -$0 |
ELEV -$0 |
OCEA -$0 |
ENVB -$0 |
Quarterly Earnings Growth | 100% | 4/17 | CVAC 794% |
RETA 362% |
KRYS 182% |
MRNA 100% |
RAIN 84% |
DNA 81% |
AVRO 72% |
OCEA 61% |
HEPA 54% |
ENVB 26% |
NVAX 7% |
VRTX 1% |
BEAM -1% |
NTLA -11% |
ELEV -21% |
EDIT -38% |
CWBR -59% |
Annual Earnings Growth | 71% | 4/17 | CVAC 144% |
KRYS 133% |
RETA 72% |
MRNA 71% |
RAIN 63% |
BEAM 58% |
HEPA 57% |
ENVB 55% |
OCEA 50% |
DNA 21% |
CWBR 1% |
ELEV -2% |
NTLA -6% |
EDIT -27% |
AVRO -59% |
VRTX -113% |
NVAX -759% |
Quarterly Revenue Growth | 2% | 6/17 | CVAC 2896% |
RETA 2885% |
NVAX 283% |
DNA 61% |
VRTX 12% |
MRNA 2% |
EDIT 0% |
KRYS 0% |
CWBR 0% |
AVRO 0% |
HEPA 0% |
RAIN 0% |
ELEV 0% |
OCEA 0% |
ENVB 0% |
BEAM -17% |
NTLA -24% |
Annual Revenue Growth | 77% | 5/17 | CVAC 1284% |
EDIT 613% |
RETA 596% |
BEAM 351% |
MRNA 77% |
VRTX 7% |
KRYS 0% |
CWBR 0% |
AVRO 0% |
HEPA 0% |
RAIN 0% |
ELEV 0% |
OCEA 0% |
ENVB 0% |
NTLA -18% |
DNA -27% |
NVAX -32% |
Cash On Hand | $1.6 Billion | 2/17 | VRTX $5.2B |
MRNA $1.6B |
DNA $616.2M |
CVAC $605.3M |
NVAX $573.6M |
KRYS $374.0M |
BEAM $230.2M |
NTLA $120.5M |
EDIT $95.8M |
AVRO $90.8M |
RETA $48.8M |
ELEV $48.2M |
CWBR $6.2M |
ENVB $3.1M |
HEPA $1.5M |
RAIN $239,857 |
OCEA -$0 |
Short Term Debt | $0 | 12/17 | NTLA $19.2M |
EDIT $16.4M |
BEAM $12.9M |
OCEA $12.8M |
NVAX $9.7M |
CVAC $5.7M |
RETA $2.5M |
HEPA $2.2M |
KRYS $1.3M |
RAIN $806,929 |
AVRO $224,000 |
MRNA -$0 |
VRTX -$0 |
CWBR -$0 |
ELEV -$0 |
ENVB -$0 |
DNA -$0 |
Long Term Debt | $1.3 Billion | 2/17 | VRTX $1.7B |
MRNA $1.3B |
DNA $445.6M |
BEAM $298.3M |
NVAX $223.6M |
RETA $163.5M |
NTLA $82.4M |
CVAC $38.3M |
ELEV $31.0M |
EDIT $22.1M |
KRYS $0 |
CWBR $0 |
AVRO $0 |
HEPA $0 |
RAIN $0 |
OCEA $0 |
ENVB $0 |
PE | -1.00 | 4/17 | KRYS 83.10 |
CVAC 6.80 |
AVRO 0.17 |
MRNA -1.00 |
NVAX -1.00 |
VRTX -1.00 |
RETA -1.00 |
EDIT -1.00 |
NTLA -1.00 |
CWBR -1.00 |
HEPA -1.00 |
BEAM -1.00 |
RAIN -1.00 |
ELEV -1.00 |
OCEA -1.00 |
ENVB -1.00 |
DNA -1.00 |
PS | 2.31 | 7/17 | RETA 269.17 |
NTLA 22.48 |
KRYS 18.02 |
VRTX 11.05 |
BEAM 6.77 |
DNA 3.25 |
MRNA 2.31 |
EDIT 1.59 |
NVAX 1.42 |
CVAC 1.26 |
CWBR -1.00 |
AVRO -1.00 |
HEPA -1.00 |
RAIN -1.00 |
ELEV -1.00 |
OCEA -1.00 |
ENVB -1.00 |
PB | 0.99 | 7/17 | RETA 75.22 |
VRTX 7.50 |
KRYS 4.91 |
BEAM 2.99 |
CVAC 1.03 |
NTLA 1.01 |
MRNA 0.99 |
DNA 0.89 |
ENVB 0.77 |
EDIT 0.56 |
ELEV 0.53 |
CWBR 0.13 |
AVRO 0.06 |
NVAX 0.00 |
HEPA 0.00 |
RAIN 0.00 |
OCEA 0.00 |
PC | 7.15 | 7/17 | RETA 134.44 |
RAIN 108.73 |
VRTX 22.38 |
KRYS 11.64 |
BEAM 10.28 |
NTLA 8.04 |
MRNA 7.15 |
NVAX 2.19 |
HEPA 1.42 |
CVAC 1.36 |
DNA 1.15 |
EDIT 1.03 |
ENVB 0.98 |
ELEV 0.76 |
CWBR 0.19 |
AVRO 0.06 |
OCEA -1.00 |
Liabilities to Equity | 0.32 | 7/17 | RETA 4.76 |
EDIT 0.87 |
DNA 0.86 |
ELEV 0.53 |
BEAM 0.48 |
VRTX 0.42 |
MRNA 0.32 |
CWBR 0.32 |
NTLA 0.22 |
ENVB 0.21 |
CVAC 0.18 |
KRYS 0.11 |
AVRO 0.04 |
NVAX 0.00 |
HEPA 0.00 |
RAIN 0.00 |
OCEA 0.00 |
ROA | -0.14 | 6/17 | AVRO 33% | CVAC 14% | KRYS 5% | VRTX -2% | BEAM -12% | MRNA -14% | RETA -16% | NVAX -17% | ELEV -39% | DNA -44% | NTLA -45% | EDIT -64% | CWBR -99% | ENVB -206% | HEPA -611% | OCEA -2352% | RAIN -4232% |
ROE | -0.19 | 10/17 | HEPA 5583% |
RAIN 3979% |
NVAX 54% |
AVRO 34% |
OCEA 27% |
CVAC 17% |
KRYS 6% |
VRTX -3% |
BEAM -18% |
MRNA -19% |
NTLA -54% |
ELEV -60% |
DNA -82% |
RETA -94% |
EDIT -120% |
CWBR -131% |
ENVB -249% |
Current Ratio | 4.08 | 7/17 | AVRO 26.32 |
KRYS 10.18 |
CVAC 6.60 |
ENVB 5.71 |
NTLA 5.57 |
CWBR 4.17 |
MRNA 4.08 |
VRTX 3.36 |
BEAM 3.08 |
ELEV 2.88 |
DNA 2.17 |
EDIT 2.16 |
RETA 1.21 |
HEPA 0.90 |
NVAX 0.76 |
RAIN 0.48 |
OCEA 0.01 |
Quick Ratio | 0.42 | 13/17 | KRYS 83.10 |
CVAC 6.80 |
AVRO 0.17 |
MRNA -1.00 |
NVAX -1.00 |
VRTX -1.00 |
RETA -1.00 |
EDIT -1.00 |
NTLA -1.00 |
CWBR -1.00 |
HEPA -1.00 |
BEAM -1.00 |
RAIN -1.00 |
ELEV -1.00 |
OCEA -1.00 |
ENVB -1.00 |
DNA -1.00 |
Long Term Debt to Equity | 0.11 | 6/17 | RETA} 1.87 |
DNA} 0.56 |
ELEV} 0.45 |
BEAM} 0.38 |
EDIT} 0.13 |
MRNA} 0.11 |
VRTX} 0.11 |
NTLA} 0.09 |
CVAC} 0.05 |
KRYS} 0.00 |
CWBR} 0.00 |
AVRO} 0.00 |
HEPA} 0.00 |
RAIN} 0.00 |
OCEA} 0.00 |
ENVB} 0.00 |
NVAX} -0.42 |
Debt to Equity | 0.11 | 6/17 | RETA 1.90 |
DNA 0.56 |
ELEV 0.45 |
EDIT 0.22 |
BEAM 0.20 |
MRNA 0.11 |
VRTX 0.11 |
NTLA 0.11 |
CVAC 0.06 |
KRYS 0.00 |
CWBR 0.00 |
AVRO 0.00 |
ENVB 0.00 |
OCEA -0.13 |
NVAX -0.44 |
RAIN -1.00 |
HEPA -5.47 |
Burn Rate | 41.98 | 1/17 | MRNA 41.98 |
AVRO 13.22 |
DNA 8.30 |
NVAX 4.32 |
ELEV 3.41 |
BEAM 2.06 |
ENVB 1.49 |
EDIT 1.43 |
CWBR 1.43 |
NTLA 0.84 |
HEPA 0.28 |
RAIN 0.07 |
OCEA 0.00 |
RETA -0.26 |
CVAC -1.49 |
VRTX -5.36 |
KRYS -13.92 |
Cash to Cap | 0.14 | 10/17 | AVRO 17.33 |
CWBR 5.20 |
ELEV 1.32 |
ENVB 1.02 |
EDIT 0.98 |
DNA 0.87 |
CVAC 0.74 |
HEPA 0.70 |
NVAX 0.46 |
MRNA 0.14 |
NTLA 0.12 |
BEAM 0.10 |
KRYS 0.09 |
VRTX 0.04 |
RETA 0.01 |
RAIN 0.01 |
OCEA 0.00 |
CCR | -132.08 | 16/17 | KRYS 2.13 |
DNA 2.10 |
VRTX 1.43 |
ELEV 1.29 |
NVAX 1.20 |
AVRO 1.11 |
CVAC 1.04 |
BEAM 0.93 |
EDIT 0.89 |
NTLA 0.63 |
HEPA 0.52 |
ENVB 0.44 |
CWBR 0.42 |
OCEA 0.16 |
RETA -0.36 |
MRNA -132.08 |
RAIN |
EV to EBITDA | -163.03 | 17/17 | KRYS} 177.39 |
VRTX} 101.86 |
CVAC} 1.05 |
EDIT} -0.66 |
CWBR} -1.00 |
AVRO} -1.00 |
HEPA} -1.00 |
RAIN} -1.00 |
ELEV} -1.00 |
OCEA} -1.00 |
ENVB} -1.00 |
NVAX} -6.82 |
NTLA} -7.00 |
DNA} -9.74 |
BEAM} -25.20 |
RETA} -82.50 |
MRNA} -163.03 |
EV to Revenue | 2.25 | 7/17 | RETA 273.97 |
NTLA 22.04 |
KRYS 16.48 |
VRTX 10.72 |
BEAM 6.57 |
DNA 2.47 |
MRNA 2.25 |
NVAX 1.03 |
EDIT 0.66 |
CVAC 0.66 |
CWBR -1.00 |
AVRO -1.00 |
HEPA -1.00 |
RAIN -1.00 |
ELEV -1.00 |
OCEA -1.00 |
ENVB -1.00 |